Summary:
Click image to enlargePhase 3, multicenter, randomized, double-blind, group sequential, placebo-controlled study to assess efficacy and safety of rimegepant for the treatment of migraine (with or without aura) in children and adolescents ≥ 6 to < 18 years of age
Qualified Participants May Receive:
All study related care at no cost
Compensation of $50 for time and travel for each completed visit